Patent · US Active

P38 MAP kinase inhibitors

US10144721B2 · kind B2 · utility

0Cited by
2References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 6, 2016
Grant dateDec 4, 2018
Priority date
Expiry dateJan 6, 2036

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P37/08
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.